Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

FDA approves generic Risperidone for the treatment of schizophrenia, bipolar disorder

The U.S. Food and Drug Administration today approved the first generic versions of Risperdal (risperidone) tablets. Risperdal is an antipsychotic drug used for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions.

1 Jul 2008

Warning about use of psychiatric drugs with the elderly

Health officials in the U.S. are warning doctors that prescribing certain psychiatric drugs to elderly people suffering from dementia can increase their risk of death.

17 Jun 2008

Antipsychotic drugs get FDA label changes

The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to make safety-related changes to prescribing information, or labeling, to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia.

16 Jun 2008

Bill 'best way to ensure' transparency of possible conflicts of interest, editorial states

A report published last week that found three researchers from Harvard Medical School were "vastly underreporting their income from drug companies" offers "striking proof that today's requirements for reporting payments from industry -- essentially an honor system in which researchers are supposed to reveal their outside income to their institutions" -- must "be strengthened," a New York Times editorial states.

11 Jun 2008

Antipsychotic drugs dangerous for the elderly

A Canadian study has found that prescribing antipsychotic drugs for elderly people may be dangerous.

27 May 2008

Spectral Modeling technology substantiated through creation of antipsychotic bank of drug candidates

LIUS Molecular Design is pleased to announce that it has successfully created two antipsychotic drug candidates with third party confirmation of predicted biological activities via in vitro testing.

19 May 2008

Hopkins researchers discover new link to schizophrenia

Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors. The finding raises the possibility that this enzyme may participate in the development of schizophrenia and related psychiatric disorders and therefore may provide a new target for developing therapies.

8 May 2008

Lack of motivation in schizophrenia linked to brain chemical imbalance

A study of patients with psychotic illnesses such as schizophrenia suggests an alternative explanation for why many sufferers lack motivation. The research is described in BioMed Central's journal BMC Psychiatry.

8 May 2008

Nurse care for schizophrenia patients

Drug and psychosocial interventions for the symptoms of schizophrenic disorders contribute to a lower incidence and prevalence of schizophrenia. Nurses will be able to offer better care through the use of nursing models and theories in the care of Schizophrenics.

6 May 2008

Antipsychotic drugs increase risk of developing pneumonia in elderly

Elderly patients who use antipsychotic drugs have a 60 percent increased risk of developing pneumonia compared to non-users.

16 Apr 2008

Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected

Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.

8 Apr 2008

Aripiprazole has potential for treating alcohol dependence

Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol. Future research will need to examine the beneficial versus the side effects of aripiprazole for treatment of alcohol dependence.

4 Apr 2008

Restrictive drug policies often cause schizophrenic patients to discontinue medication

Policies requiring authorization before physicians can prescribe newer medications to schizophrenic patients may be counter-productive.

2 Apr 2008

Researchers may have found test for depression

Researchers from the University of Illinois at Chicago College of Medicine have discovered that a change in the location of a protein in the brain could serve as a biomarker for depression, allowing a simple, rapid, laboratory test to identify patients with depression and to determine whether a particular antidepressant therapy will provide a successful response.

12 Mar 2008

New discovery could change future diagnosis and therapy of depression

12 Mar 2008

Genetic variations increase risk of anxiety disorders

Massachusetts General Hospital (MGH) researchers - in collaboration with scientists at the University of California at San Diego and Yale University - have discovered perhaps the strongest evidence yet linking variation in a particular gene with anxiety-related traits.

4 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Treatment of children and adolescents with schizophrenia

There is a wealth of scientific literature available on the treatment of adults diagnosed with schizophrenia.